For the Inventor, By the Inventor

Enter assignee name

Canbas Co., Ltd.

Calculating rank

USPTO Granted Patents = 15

% Expired Patents = 20.0

CIPO Patents = 1

EPO Patents = 5

Forward Citations = 31

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Takumi Kawabe (15 out of 17 patents)

Hidetaka Kobayashi (7 out of 9 patents)

Takuji Sato (5 out of 7 patents)

4. Sayaka Yamamoto (3 out of 3 patents)

5. Machiyo Ishigaki (2 out of 2 patents)

6. Yoko Hasegawa (2 out of 2 patents)

7. Masashi Suganuma (2 out of 2 patents)

8. Akira Asai (1 out of 5 patents)

9. Naohisa Ogo (1 out of 5 patents)

10. Daisuke Muraoka (1 out of 4 patents)

11. Naoki Mine (1 out of 1 patent)

12. Naoya Saito (1 out of 1 patent)

13. Keiichi Sakakibara (1 out of 1 patent)

14. Jonathan M Friedman (1 out of 1 patent)

15. Toshiyuki Hibino (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 12239714 - Phosphatidylserine-binding conjugates (2025-03-04),

2. 12209079 - IDO/TDO inhibitor (2025-01-28),

3. 10149887 - Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment (2018-12-11),

4. 9221872 - Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations (2015-12-29),

5. 8415357 - Compounds with anti-cancer activity (2013-04-09),

6. 8084454 - Compounds with anti-cancer activity (2011-12-27),

7. 7851592 - Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents (2010-12-14),

8. 7652042 - Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2010-01-26),

9. 7629364 - Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2009-12-08),

10. 7407985 - Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2008-08-05),

11. 7358046 - Sensitivity test to predict efficacy of anti-cancer therapies (2008-04-15),

12. 7125842 - Anti-fungal compounds and methods of use (2006-10-24),

13. 7030111 - Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments (2006-04-18),

14. 6995135 - Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments (2006-02-07),

15. 6881575 - Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents (2005-04-19),

Company Overview

Canbas Co., Ltd. is a Japanese company based in Numazu, specializing in the development and manufacturing of advanced materials and innovative solutions for various industries. The organization focuses on research and technology in fields such as electronics, automotive components, and environmental sustainability. With a commitment to enhancing product performance and efficiency, Canbas aims to contribute to technological advancements and support the evolving needs of its clients across diverse sectors.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

15 Patents

#2 in Numazu

#3,448 in Japan

#39,991 in the World

Canbas Co., Ltd.

Forward Citations = 31

18 inventors:

Takumi Kawabe (15 out of 17 patents)

Hidetaka Kobayashi (7 out of 9 patents)

Takuji Sato (5 out of 7 patents)

4. Sayaka Yamamoto (3 out of 3 patents)

5. Machiyo Ishigaki (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Canbas Co., Ltd.. Retrieved from https://idiyas.com/company/canbas-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…